Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor

This study is currently recruiting participants.
Verified May 2012 by Chinese University of Hong Kong
Sponsor:
Information provided by (Responsible Party):
Eddie SY Chan, MD, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01581723
First received: March 21, 2012
Last updated: June 26, 2013
Last verified: May 2012
  Purpose

Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor. For many years, monopolar transurethral resection of bladder tumor (TURP) has been the gold standard for treatment. However, complications including bleeding, bladder perforation and inadequate sampling of deep tumor biopsy remain the major concerns. Recently published papers suggested that the newer bipolar TUR technology has similar surgical outcomes but less complications comparing with monopolar TUR. In this study, investigators will investigate the benefit of new technology as compared with conventional monopolar resection on tumor clearance, complication and recurrence rates.


Condition Intervention Phase
Urinary Bladder Tumor
Device: Monopolar diathermy
Device: Bipolar diathermy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • Muscle sampling rate [ Time Frame: An expected average of 7 days post operation ] [ Designated as safety issue: No ]
    To assess the charring effect to the integrity of the tumor base biopsy

  • Incidence of TUR syndrome [ Time Frame: Intra-operation and up to 7 days post operation ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Recurrence rate of bladder cancer [ Time Frame: 3 months and 6 months after surgery ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: May 2012
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Monopolar TUR
Monopolar diathermy is used to perform tranurethral resection of bladder tumor
Device: Monopolar diathermy
monopolar diathermy
Other Names:
  • Olympus Monopolar HF-resection Electrode
  • Model: A22205A
Experimental: Biploar TUR
Bipolar diathermy is used to perform transurethral resection of bladder tumor
Device: Bipolar diathermy
bipolar diathermy
Other Names:
  • Olympus TURis Bipolar HF-resection electrode
  • Model: WA22306D

Detailed Description:

Transurethral resection (TUR) of bladder tumor is one of commonest procedures in urology practice. It is the surgery of choice for staging and treating non-muscle invasive bladder cancer. Short lengths of hospital stay, simple and safe are the main advantages of the surgery. Conventional TUR is performed with monopolar diathermy, which commonly elicits obturator reflexes in lateral-located tumor. However, it is not without complication. Bleeding and bladder perforation with or without obturator reflex are the most significant complications after TUR of bladder tumor. The charring effect of monopolar is also a concern as the diagnosis of muscle invasion by tumor is determined by the integrity of tumor base biopsy. Mariappan et al. reported that as high as 33% of the specimen had no detrusor muscle present for assessment. The absent of muscle not only affect the staging procedure but also associated with higher cancer recurrence rate.

Bipolar resection has been widely used in transurethral resection of prostate (TURP). As compared with the traditional monopolar technology, the electric current passes through the instrument sheath. The advantage of bipolar technology includes less obturator reflex, good hemostasis and early recovery. Study has showed that the cautery artifact is more severe on monopolar resection as compared with bipolar in prostate tissues. Due to the clean and precise cutting, there will be less charring on the specimen and thermal injury to peripheral tissues. Applying to bladder tumor resection, this will improve the staging accuracy with better determination of the depth of invasion. Furthermore, with the use of saline instead of glycine as irrigation fluid, risk of TUR syndrome is minimized. There is no randomized trial on the benefit of using bipolar instrument on TUR bladder cancer. In this study, investigator will investigate the role of bipolar technology in TUR bladder cancer as compared with traditional monopolar resection.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult male or female patients (age ≥ 18)
  • Patients who have diagnosed with bladder cancer (either primary or recurrent) by cystoscopy

Exclusion Criteria:

  • Patients who are scheduled for second TUR within 6 weeks after the previous TUR
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01581723

Contacts
Contact: Eddie SY Chan, MD +852 2632 2625 eddie@surgery.cuhk.edu.hk
Contact: Cleo NY Lam, BSc +852 2632 1663 nylam@surgery.cuhk.edu.hk

Locations
Hong Kong
Prince of Wales Hospital Recruiting
Shatin, Hong Kong
Principal Investigator: Eddie SY Chan, MD         
Sub-Investigator: Chi Fai Ng, MD         
Sub-Investigator: Simon SM Hou, MBBS         
North District Hospital Not yet recruiting
Sheung Shui, Hong Kong
Sub-Investigator: Ho Yuen Cheung, MBChB         
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: Eddie SY Chan, MD Chinese University of Hong Kong
  More Information

No publications provided

Responsible Party: Eddie SY Chan, MD, Dr., Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT01581723     History of Changes
Other Study ID Numbers: CUHK_TURB_2012
Study First Received: March 21, 2012
Last Updated: June 26, 2013
Health Authority: Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Keywords provided by Chinese University of Hong Kong:
urinary bladder tumor
monopolar TURBT
bipolar TURBT

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on April 17, 2014